Medical Journals

Effects of Dose and Duration of Continuous Gnrh-agonist Treatment on Induction of Estrus in Beagle Dogs: Competing and Concurrent Up-regulation and Down-regulation of Lh Release.

Authors:
  • Concannon P W
  • Temple M
  • Montanez A
  • Newton L

From: Department of Biological Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA. pwc1@cornell.edu

Theriogenology

  • Publish Date: Oct 2006
  • ISSN: 0093-691X
  • Volume: 66
  • Issue: 6-7
  • Pages: 1488-96
  • Medium: Print
  • Language: English
  • Citation (JAMA): Concannon P W, Temple M, Montanez A, et al. Effects of Dose and Duration of Continuous Gnrh-agonist Treatment on Induction of Estrus in Beagle Dogs: Competing and Concurrent Up-regulation and Down-regulation of Lh Release.. Theriogenology Oct 2006;66:1488-96

Abstract

Dose-response estrus-induction trials were conducted during anestrus in 93 treated and 6 control bitches, a continuous administration of the GnRH-agonist lutrelin with a potency 150 x GnRH, and at six different doses from 0.2 to 4.8 microg/kg/d for 7-14 days in 15 groups of six to eight dogs each in defined stages of natural or pharmacologically determined anestrus. Agonist treatment induced clinically and cytologically normal proestrus (in 89% of cases) within 4.8 +/- 0.2 x days, and resulted in behavioral estrus (71%), spontaneous late-proestrus LH (and FSH) surges, ovulation (59%) and pregnancy (44%) in a dose dependent manner. Outcomes of ovulation and pregnancy in most cases required that the dose be sufficiently large enough to routinely stimulate a large initial increase in LH and FSH (i.e., > or = 0.6 microg/kg/d), and of sufficient duration (i.e., > 7 days) to ensure that supra-basal gonadotropin levels persistedntil no longer needed for spontaneous continuation of an induced proestrus. Success additionally required that the GnRH dose be modest enough (i.e., < 1.8 microg/kg/d) to not excessively down-regulate spontaneous pre-ovulatory surge release of gonadotropin or be removed shortly before or at the time when the LH surges typically occurred (10-13 days after initiation of treatment). The 1.8 microg dose was compared to saline to assess the time course of its down-regulation action on serum LH in six ovariohysterectomized bitches compared to four saline-related controls. Results in intact bitches receiving the 1.8-microg doses demonstrated an LH-releasing effect for 10-11 days that overlapped a period of obvious down-regulation seen with the same dose after 3 days in the ovariohysterectomized bitches. In the latter, however, complete down-regulation to anestrus-like values did not occur until after 18-21 days of treatment. A dose of 0.6 microg/kg/d for 12 days yielded the best estrus-induction results, including pregnancy rates of 100% in six bitches treated in natural-anestrus bitches, six bitches in which anestrus had been advanced by a luteolytic prostaglandin treatment and in six bitches in which anestrus had been extended by progesterone implants administered for 3 months. Although lutrelin is not commercially available, these results provide guidelines for the development of estrus-inducing protocols with other GnRH-agonists of known biopotencies.

Mesh Headings (Keywords): Anestrus, Animals, Dogs, Dose-Response Relationship, Drug, Down-Regulation, Drug Administration Schedule, Estradiol, Estrus, Female, Fertility Agents, Female, Gonadotropin-Releasing Hormone, Luteinizing Hormone, Male, Ovulation Induction, Pregnancy, Progesterone, Up-Regulation


Check for Full Text / PubMed Unique Identifier (PMID): 16563490


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.